Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIKI NASDAQ:BASI OTCMKTS:BIOQ NASDAQ:CBLI OTCMKTS:HPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIKIAIkido Pharma$5.04-1.2%$5.26$3.31▼$11.48$27.64M0.9379,326 shs128,080 shsBASIBioanalytical Systems$2.12+3.4%$18.71$3.05▼$21.08$23.60M1.92122,925 shs556,278 shsBIOQBioqual$43.44-1.8%$45.93$43.44▼$72.50$39.58M-0.112 shs700 shsCBLICleveland BioLabs$3.19$1.62▼$10.97$5K0.7271,922 shs5,046 shsHPPIHedgePath Pharmaceuticals$0.04-8.5%$0.05$0.04▼$0.32$16.26M-1.1619,283 shs9,800 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIKIAIkido Pharma-3.23%-6.25%-5.56%+51.34%+168.42%BASIBioanalytical Systems-1.91%+12.64%-23.79%-15.29%+22.75%BIOQBioqual0.00%0.00%0.00%-19.55%-38.97%CBLICleveland BioLabs0.00%0.00%0.00%0.00%-50.00%HPPIHedgePath Pharmaceuticals0.00%+2.35%-11.11%-12.73%-40.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIKIAIkido PharmaN/AN/AN/AN/AN/AN/AN/AN/ABASIBioanalytical SystemsN/AN/AN/AN/AN/AN/AN/AN/ABIOQBioqualN/AN/AN/AN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/AN/AN/AN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIKIAIkido Pharma 0.00N/AN/AN/ABASIBioanalytical Systems 0.00N/AN/AN/ABIOQBioqual 0.00N/AN/AN/ACBLICleveland BioLabs 0.00N/AN/AN/AHPPIHedgePath Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIKIAIkido PharmaN/AN/AN/AN/A$19.27 per shareN/ABASIBioanalytical Systems$60.47M0.39$0.00 per share558.40$0.69 per share3.07BIOQBioqual$58.59M0.66N/AN/AN/A∞CBLICleveland BioLabs$260K0.00N/AN/A$0.87 per share0.00HPPIHedgePath PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIKIAIkido Pharma-$7.17M-$3.88N/AN/AN/AN/A-18.21%-16.94%N/ABASIBioanalytical Systems-$4.68M-$0.35N/A53.00N/A-7.75%-42.74%-6.38%N/ABIOQBioqual$480K-$2.39N/A∞N/A-4.34%-5.82%-3.79%N/ACBLICleveland BioLabs-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/AHPPIHedgePath Pharmaceuticals-$4.55MN/A0.00∞N/AN/AN/A-246.03%N/ALatest CBLI, BASI, BIOQ, AIKI, and HPPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/11/2025Q3 2025BIOQBioqualN/A$1.05N/A$1.05N/A$14.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIKIAIkido PharmaN/AN/AN/AN/AN/ABASIBioanalytical SystemsN/AN/AN/AN/AN/ABIOQBioqual$0.501.15%N/AN/A N/ACBLICleveland BioLabsN/AN/AN/AN/AN/AHPPIHedgePath PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIKIAIkido PharmaN/A29.5429.54BASIBioanalytical Systems2.490.480.46BIOQBioqualN/A5.085.08CBLICleveland BioLabsN/A45.9345.93HPPIHedgePath PharmaceuticalsN/A6.766.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIKIAIkido Pharma10.88%BASIBioanalytical Systems10.62%BIOQBioqualN/ACBLICleveland BioLabs5.09%HPPIHedgePath PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAIKIAIkido Pharma8.60%BASIBioanalytical Systems11.46%BIOQBioqual39.24%CBLICleveland BioLabs1.03%HPPIHedgePath Pharmaceuticals4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIKIAIkido Pharma45.49 million5.01 millionNot OptionableBASIBioanalytical Systems39711.13 millionN/ANot OptionableBIOQBioqual114890,000543,000Not OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableHPPIHedgePath Pharmaceuticals1370.45 millionN/ANot OptionableCBLI, BASI, BIOQ, AIKI, and HPPI HeadlinesRecent News About These CompaniesEagle Pharmaceuticals Inc.February 17, 2024 | wsj.comMedia Sentiment Over TimeCBLI, BASI, BIOQ, AIKI, and HPPI Company DescriptionsAIkido Pharma NASDAQ:AIKI$5.04 -0.06 (-1.18%) As of 07/8/2025AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Bioanalytical Systems NASDAQ:BASIBioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Bioqual OTCMKTS:BIOQ$43.44 -0.81 (-1.83%) As of 03:59 PM EasternBioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.Cleveland BioLabs NASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.HedgePath Pharmaceuticals OTCMKTS:HPPI$0.04 0.00 (-8.54%) As of 07/8/2025HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
